Bain Capital Life Sciences secures $3 billion for fourth fund

12 September 2024

Bain Capital Life Sciences has announced the closing of its fourth fund, securing approximately $3 billion in total commitments.

The fund includes around $2.5 billion from existing and new investors, while Bain Capital partners, employees, and affiliates contributed the remaining amount, continuing the firm’s tradition of being the largest investor in its funds.

The new fund aims to leverage the group’s investment experience to support medicines, medical devices, diagnostics, and life sciences tools targeting unmet medical needs globally.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical